Molecular modelling to help create better, safer drugs
How our bodies break down the common drugs ibuprofen, diclofenac and warfarin is the subject of a new study from the University of Bristol, published in the Journal of the American Chemical Society. The research should ultimately help predict how new drugs will be metabolized in the body, potentially helping avoid adverse drug reactions in future. (Source: University of Bristol news)
Source: University of Bristol news - May 23, 2013 Category: Universities & Medical Training Authors: news_text Tags: Press releases Source Type: news
Some Pain Drugs Increase the Risk of Heart Attack
ROCHESTER, Minn. — Some of the most common pain drugs used by older adults who experience discomfort in muscles and joints can increase the risk of heart attack and stroke. The April issue of Mayo Clinic Health Letter covers the risks of nonsteroidal anti-inflammatory drugs (NSAIDs) that include celecoxib (Celebrex), diclofenac (Voltaren), ibuprofen (Advil, Motrin [...] (Source: Mayo Clinic Health Information)
Source: Mayo Clinic Health Information - April 26, 2013 Category: Consumer Health News Source Type: news
Acute Pain Yields to Lower-Dose Diclofenac
(MedPage Today) -- FORT LAUDERDALE, Fla. - Lower-dose submicron particle diclofenac offered good pain control compared with placebo, researchers reported here. (Source: MedPage Today Pain Management)
Source: MedPage Today Pain Management - April 15, 2013 Category: Anesthesiology Source Type: news
Submicron NSAIDs Demonstrate Efficacy At Lower Doses In Studies In Patients With Acute And Chronic Pain
Iroko Pharmaceuticals, LLC, a Philadelphia-based pharmaceutical company focused on the development and commercialization of innovative therapeutic products, is presenting positive Phase 3 data from its investigational submicron non-steroidal anti-inflammatory drug (NSAID) pipeline at two medical meetings. These presentations summarize the results of studies of lower dose submicron indomethacin in patients with post surgical pain, and lower dose submicron diclofenac in patients with osteoarthritis pain... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 15, 2013 Category: Consumer Health News Tags: Pain / Anesthetics Source Type: news
Iroko reports positive results from Phase III submicron indomethacin and diclofenac studies
Iroko Pharmaceuticals has reported positive results from its Phase III studies of lower dose submicron indomethacin in patients with post-surgical pain, and lower dose submicron diclofenac in patients with osteoarthritis pain. (Source: Drug Development Technology)
Source: Drug Development Technology - April 11, 2013 Category: Pharmaceuticals Source Type: news
H2O dear: The rising problem of drugs in our water supplies
And how official wrangling is delaying action in Europe (Source: Alliance for Natural Health)
Source: Alliance for Natural Health - April 3, 2013 Category: Complementary Medicine Authors: Yvonne Tags: 17-alpha-ethinylestradiol 17-beta-oestradiol agricultural runoff antibiotics bisphenol A contraceptive drug diclofenac drugs endocrine-disrupting ENVI Environmental Protection Agency EU legislation europe European Council Europ Source Type: news
diclofenac, Voltaren, Cataflam, Voltaren-XR, Cambia
Title: diclofenac, Voltaren, Cataflam, Voltaren-XR, CambiaCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 3/26/2013 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - March 26, 2013 Category: Rheumatology Source Type: news
Seven million 'take painkillers so they can work'
More than seven million people are taking painkillers on a regular basis just to feel well enough to go to work, according to a survey. (Source: Telegraph Health)
Source: Telegraph Health - February 26, 2013 Category: Consumer Health News Tags: ibuprofen painkillers tramadol diclofenac codeine Source Type: news
Reumofan Plus USA, LLC and Reumofan USA, LLC is Voluntarily Recalling all lots of Reumofan Plus Tablets Due to Undeclared Drug Ingredients
Feb. 15, 2013 - SPRINGFIELD, Pa., /PRNewswire/-- Reumofan Plus USA, LLC and Reumofan USA, LLC is recalling "Reumofan Plus" Tablets, Lot# 99515, exp. 09/16, because they contain undeclared active pharmaceutical ingredients: methocarbamol, dexamethasone, and diclofenac. Use of this product could result in serious and life-threatening injuries (Source: Food and Drug Administration)
Source: Food and Drug Administration - February 19, 2013 Category: Food Science Source Type: news
Vioxx and Diclofenac: Why Are Two Heart Risky Pain Drugs Viewed Differently?
More than a decade ago, Merck launched Vioxx (rofecoxib), one of the first of a new class of pain relievers known as COX-2 inhibitors. These compounds, by virtue of their mode of action, were deemed to be as potent arthritis pain relievers as traditional non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen, but were believed to be safer than NSAIDs since they caused less gastrointestinal distress. Vioxx was an immediate success with physicians and patients. New prescriptions for Vioxx soared. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: John LaMattina Source Type: news
Reumofan Plus: Recall - Undeclared Drug Ingredient
[UPDATED 2/19/2013]
Reumofan Plus USA, LLC and Reumofan USA, LLC is recalling "Reumofan Plus" Tablets, Lot# 99515, exp. 09/16, because they contain undeclared active pharmaceutical ingredients: methocarbamol, dexamethasone, and diclofenac. The... (Source: Drugs.com - FDA MedWatch Alerts)
Source: Drugs.com - FDA MedWatch Alerts - February 19, 2013 Category: Drugs & Pharmacology Source Type: news
Uganda: Painkiller 'Diclofenac' Linked to Heart Attack
[New Vision]Diclofenac, a pain killer that increases the risk of heart attack and stroke, is easily accessible across Uganda. Virtually, every drug shop and pharmacy is selling it without prescription. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 18, 2013 Category: African Health Source Type: news
NSAIDs and cardiovascular risk: An examination of sales and Essential Medicines Lists in low-, middle-, and high-income countries
Source: PLoS Medicine
Area: News
It is known that certain non-steroidal anti-inflammatory drugs (NSAIDs) increase the risk of myocardial infarction and stroke and should be avoided in patients at high risk of cardiovascular events. A study, published in PLoS medicine, investigated the extent to which evidence on cardiovascular risk with NSAIDs has translated into guidance and sales in 15 countries.
The authors identified that three drugs (rofecoxib, diclofenac, and etoricoxib) ranked consistently highest in terms of cardiovascular risk compared with nonuse and naproxen was associated with a low risk. Diclofenac...
Source: NeLM - Cardiovascular Medicine - February 15, 2013 Category: Cardiology Source Type: news
Researchers say diclofenac is over-prescribed
New research suggests a painkiller which has a high risk of heart attack and stroke compared to other options may be over-prescribed. The study looked at 15 coun (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 14, 2013 Category: Drugs & Pharmacology Source Type: news
Diclofenac and CVD risksDiclofenac and CVD risks
Diclofenac, which is listed on the essential-medicine lists of 74 countries, increased the risk of cardiovascular events between 38% and 63% in different studies. The increased risk with diclofenac was similar to the COX-2 inhibitor rofecoxib, a drug withdrawn from worldwide markets because of cardiovascular toxicity. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 13, 2013 Category: Cardiology Tags: Cardiology News Source Type: news
